Most Anticipated New Drug Launches of 2025 The pharmaceutical industry is set for another groundbreaking year in 2025, with several...

Novartis has announced plans to acquire Anthos Therapeutics, a biopharmaceutical company specializing in cardiovascular treatments, for...

Top selling drugs of 2024 Sl No Brand Q1 Revenues 1 Keytruda $29.5 billion 2 Ozempic $16.7 billion 3 Dupixent $13.4 billion 4 Eliquis $...

AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has approved Enhertu (trastuzumab...

CHMP gave a positive opinion for treating BMS' cell-therapy Breyanzi for relapsed or refractory follicular lymphoma Bristol Myers Squibb...

TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2024 Sl No Company Q1 Q2 Q3 Total Best selling products 1 JOHNSON AND JOHNSON $21.8 $43.8...

Roche has announced that its investigational drug, Itovebi (inavolisib), in combination with palbociclib and fulvestrant, has...

Pfizer's Targeted Therapy Shows Promising Results for Metastatic Colorectal Cancer with BRAF V600E Mutation Pfizer has shared positive...

Sanofi announced that Sarclisa (isatuximab) has been approved by the European Union (EU) for use in combination with the standard-of-care...

Novo Nordisk has announced promising results from its STEP UP phase 3b trial, revealing that a 7.2 mg dose of semaglutide administered...

In a strategic move to advance cancer therapeutics, AbbVie and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, have...

Eli Lilly has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Omvoh (mirikizumab) as a treatment for...

Johnson & Johnson has announced a step in bolstering its leadership in neuroscience with the acquisition of Intra-Cellular Therapies, a...

GSK Showcases Strong Growth and Future Innovations at JP Morgan 2025 Healthcare Conference At the 2025 JP Morgan Healthcare Conference,...

New Subcutaneous Formulation of Sarclisa Achieves Key Objectives in IRAKLIA Phase 3 Study for Multiple Myeloma A subcutaneous (SC)...

Keytruda - $22 billion Darzalex - $9 billion Opdivo - $7 billion Imbruvica - $5billion Tagrisso - $5 billion Revlimid - $4 billion...

Valo Health and Novo Nordisk have announced an expansion of their collaboration to advance the discovery and development of innovative...

Novartis has revealed encouraging results from the Phase III STEER trial, demonstrating the effectiveness of intrathecal onasemnogene...

Expected best selling drugs of 2025 based on revenues. Revenues of Ozempic, Dupixent, Mounjaro, Skyrizi, Eliquis, Biktarvy, Wegovy, Darzalex

Bristol Myers Squibb has announced encouraging findings from two key Phase 3 trials, POETYK PsA-1 and POETYK PsA-2, evaluating...

AbbVie's recent clinical trial results for emraclidine and tavapadon reflect a mixed outcome in their efforts to advance neurological...

Koselugo (selumetinib) Shows Notable Improvement in Objective Response Rate Versus Placebo for Adults with Neurofibromatosis Type 1 and...

Dupixent - $6.8 billion Stelara - $5.3 billion Humira - $ 5.0 billion Skyrizi - $4.7 billion Cosentyx - $2.9 billion Entyvio - $2.9...

1. Keytruda: Revolutionizing Cancer Care Keytruda (pembrolizumab), an immunotherapy drug by Merck, has transformed cancer treatment....

Eisai and Biogen have announced that their humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, LEQEMBI (lecanemab),...

Overview NovoNordisk Collaboration with Omega Therapeutics and Cellarity Novartis and Voyager Collaboration to Develop Gene Therapies for...

Eli Lilly has revealed promising results from the SYNERGY-NASH study, a phase 2 clinical trial assessing tirzepatide's efficacy in...

The European Commission (EC) has granted approval for Opdivo (nivolumab) in combination with cisplatin and gemcitabine for first-line...

KEYTRUDA (pembrolizumab) achieves milestone as first immunotherapy to significantly enhance overall survival in high-risk early-stage...

New medications, Jemperli and Korsuva will be available for endometrial cancer and chronic kidney disease For women facing advanced or...

19th January, 2024 Tirzepatide Recommended alongside dietary adjustments and physical activity to enhance blood sugar management in...

The Health and Human Services Department in the United States, administered by the Centers for Medicare & Medicaid Services (CMS), is...

More than 10 million individuals enrolled in Medicare Part D received no-cost vaccines in 2023 due to the Inflation Reduction Act, a...

1. KEYTRUDA Revenues in 2023: $25 billion Company: Merck & Co. Approved Indications: Keytruda is approved for several cancer types:...

Novartis presented new data of Fabhalta showing improvement in proteinuria in patients with IgA nephropathy Novartis revealed new data...

AbbVie presented positive data of Rinvoq in patients with giant cell arteritis AbbVie released positive outcomes from the SELECT-GCA...

April 02, 2024 Abbott Secures FDA Nod for Triclip, Novel Tool for Mending Faulty Tricuspid Heart Valve Abbott revealed that the U.S. Food...

Zeposia failed to meet the efficacy endpoints in patients with Crohn's disease Bristol Myers Squibb has provided an update on the...

Approval of Truqap plus Faslodex Granted in Japan for Patients Dealing with Advanced Hormone Receptor-Positive Breast Cancer Beyfortus...

The U.S. Food and Drug Administration has given its approval for Lenmeldy (atidarsagene autotemcel), marking the first-ever...

Voydeya Received CHMP Position Opinion for Residual Haemolytic Anaemia for PNH The CHMP of the European Medicines Agency (EMA) has...

BEST SELLING DIABETES MELLITUS DRUGS IN 2023 Ozempic - $13.8 billion Trulicity - $7.1 billion Farxiga - $6.0 billion Mounjaro - $5.2...

Dupixent approved for chronic spontaneous urticaria Japan became the first country to approve Dupixent for chronic spontaneous urticaria...

Express-Scripts included the use of interchangeable insulin biosimilars, which aims to improve cost savings. Express-Scripts included the...

TOP PHARMACEUTICAL COMPANIES BY REVENUES 2023 Merck revenues exclude animal health revenues 1. JOHNSON AND JOHNSON Q1 REVENUES Johnson...

December 27, 2023 Lilly completed the acquisition of POINT Biopharma and entered the race to develop novel radiopharmaceuticals for...

DRUGS ON WHICH CMS SPENT THE MOST IN 2021 Also read: Top pharma companies by revenues in 2023 1. Eliquis (Apixaban): Indications: Eliquis...

BEST SELLING DRUGS OF 2023 | TOP 10 DRUGS BY REVENUES Also read: Top pharma companies by revenues in 2023 Top pharmaceutical companies by...

Major depression is a significant global health concern, ranking second leading cause of disability worldwide. The international...

October 03, 2023 Eli Lilly to enter the radioligand therapy field with the acquisition of POINT Biopharma. Eli Lilly and POINT Biopharma...